Mapping the effectiveness and risks of GLP-1 receptor agonists.
Xie Y, Choi T, Al-Aly Z.
Nat Med. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20.
Life of a Type 1 diabetic.
Kilbreath A.
Fam Syst Health. 2024 Dec;42(4):649-650. doi: 10.1037/fsh0000907. Epub 2024 Jul 25.
Dementia in Diabetes: The Role of Hypoglycemia.
Husain KH, Sarhan SF, AlKhalifa HKAA, Buhasan A, Moin ASM, Butler AE.
Int J Mol Sci. 2023 Jun 7;24(12):9846. doi: 10.3390/ijms24129846.
Tirzepatide associated autoimmune encephalitis: A case report.
Abdi A, Ariaei A, Hemasian H, Shahabi S, Sina F.
J Am Pharm Assoc (2003). 2025 Sep-Oct;65(5):102474. doi: 10.1016/j.japh.2025.102474. Epub 2025 Jul 1.
Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.
AbuAlrob MA, Hussein A, Abdellatif R, Itbaisha A, Zammar K, Mesraoua B.
Epilepsia. 2026 Mar;67(3):1246-1255. doi: 10.1111/epi.70022. Epub 2025 Nov 18.
Insulin use: preventable errors.
Prescrire Editorial Staff.
Prescrire Int. 2014 Jan;23(145):14-7.
[Seizures and non-ketotic hyperglycemia].
Scherer C.
Presse Med. 2005 Sep 10;34(15):1084-6. doi: 10.1016/s0755-4982(05)84123-5.
Envisioning the neuroprotective effect of Metformin in experimental epilepsy: A portrait of molecular crosstalk.
H S N, Paudel YN, K L K.
Life Sci. 2019 Sep 15;233:116686. doi: 10.1016/j.lfs.2019.116686. Epub 2019 Jul 23.
Topiramate and type 2 diabetes: an old wine in a new bottle.
Khanna V, Arumugam S, Roy S, Mittra S, Bansal VS.
Expert Opin Ther Targets. 2008 Jan;12(1):81-90. doi: 10.1517/14728222.12.1.81.
Hypoglycemic seizures and epilepsy in type I diabetes mellitus.
Falip M, Miró J, Carreño M, Jaraba S, Becerra JL, Cayuela N, Perez Maraver M, Graus F.
J Neurol Sci. 2014 Nov 15;346(1-2):307-9. doi: 10.1016/j.jns.2014.08.024. Epub 2014 Aug 27.
